Correction to: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma (Journal of Cancer Research and Clinical Oncology, (2023), 149, 8, (5007-5023), 10.1007/s00432-022-04418-y)

In Fig. 5 of this article, there were two errors in Fig. 5c, right panel. Firstly, the title of the graph (in the right panel) that had read “Target tumour” should have read “Off-target tumour”. In addition, the graph had presented the raw tumour volume data, and it should have presented the % tumour volume increase data. Asterisks that depict the level of significance had also been missing; The Fig. 5c should have appeared as shown below: (Figure presented.) Sonodynamic treatment of T110299 tumours. A % cell viability of T110299 cells treated in the absence (no HPNP) and the presence of nanoparticles (HPNP), without (no US) and with ultrasound exposure at 3 W/cm ² and 50% DC, for 30 s, at normoxic and hypoxic conditions. B In vivo treatment protocol. C Plot of % change of target and off-target tumour volumes treated with no treatment (untreated), ultrasound only (US), nanoparticles carrying hematoporphyrin (HPNP) and nanoparticles carrying hematoporphyrin with ultrasound, i.e. sonodynamic therapy, SDT, (HPNPs + US). D Plot of % change of target and off-target tumour volumes trated with SDT. E The corresponding animal body weight increase. Statistical significance was computed using Two-way ANOVA with Bonferroni post-test (A) and One-way ANOVA with Tukey multiple comparison test (C) (*p < 0.05, **p < 0.01, ***p < 0.001). For A: the asterisks show the significance of difference between samples incubated in the presence and the absence of nanoparticles, under ultrasound exposure.